Boston Scientific Balance Sheet Health
Financial Health criteria checks 4/6
Boston Scientific has a total shareholder equity of $22.4B and total debt of $11.2B, which brings its debt-to-equity ratio to 49.8%. Its total assets and total liabilities are $40.1B and $17.7B respectively. Boston Scientific's EBIT is $3.2B making its interest coverage ratio 15.4. It has cash and short-term investments of $725.0M.
Key information
49.8%
Debt to equity ratio
US$11.18b
Debt
| Interest coverage ratio | 15.4x |
| Cash | US$725.00m |
| Equity | US$22.45b |
| Total liabilities | US$17.70b |
| Total assets | US$40.14b |
Recent financial health updates
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
Mar 05
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Recent updates
Boston Scientific Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 25Estimating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Apr 23Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Apr 07Boston Scientific: Bright Future, Rather Pricey
Mar 18Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
Mar 05Boston Scientific (NYSE:BSX) Has More To Do To Multiply In Value Going Forward
Jan 29Is It Time To Consider Buying Boston Scientific Corporation (NYSE:BSX)?
Jan 15Boston Scientific Standing Apart As A Rare Med-Tech Growth Story
Jan 14Calculating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Jan 02Do Boston Scientific's (NYSE:BSX) Earnings Warrant Your Attention?
Dec 19Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05
Axonics and FARAPULSE acquisitions to skyrocket market share and revenue in medical devices
Mar 15 Uncertainty surrounding the approval and U.S. launch timeline for ACURATE neo2 might affect projected revenues from the Structural Heart Valves franchise.Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($7.3B) exceed its short term liabilities ($5.1B).
Long Term Liabilities: BSX's short term assets ($7.3B) do not cover its long term liabilities ($12.6B).
Debt to Equity History and Analysis
Debt Level: BSX's net debt to equity ratio (46.6%) is considered high.
Reducing Debt: BSX's debt to equity ratio has reduced from 74.8% to 49.8% over the past 5 years.
Debt Coverage: BSX's debt is well covered by operating cash flow (34.1%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (15.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/04 08:24 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boston Scientific Corporation is covered by 69 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| Adam Feinstein | Barclays |